Three-month treatment with pioglitazone reduces circulating levels of thiobarbituric acid-reacting substances, a marker of reactive oxidative stress, without change in body mass index, in Japanese patients with type 2 diabetes.
Nakatsuji
Hideaki
H
Kishida
Ken
K
Funahashi
Tohru
T
Shimomura
Iichiro
I
D052242:Adiponectin / Q000097:blood; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy* / Q000208:ethnology; D015536:Down-Regulation; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007564:Japan; D008297:Male; D008875:Middle Aged; D018384:Oxidative Stress / Q000187:drug effects*; D000077205:Pioglitazone; D011446:Prospective Studies; D045162:Thiazolidinediones / Q000627:therapeutic use*; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism*; D013997:Time Factors; D016896:Treatment Outcome
C499918:ADIPOQ protein, human; D052242:Adiponectin; D015415:Biomarkers; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D017392:Thiobarbituric Acid Reactive Substances; D000077205:Pioglitazone